Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arica White is active.

Publication


Featured researches published by Arica White.


Cancer Epidemiology, Biomarkers & Prevention | 2012

Patterns of Colorectal Cancer Test Use, Including CT Colonography, in the 2010 National Health Interview Survey

Jean A. Shapiro; Carrie N. Klabunde; Trevor D. Thompson; Marion R. Nadel; Laura C. Seeff; Arica White

Background: Recommended colorectal cancer (CRC) screening tests for adults ages 50 to 75 years include home fecal occult blood tests (FOBT), sigmoidoscopy with FOBT, and colonoscopy. A newer test, computed tomographic (CT) colonography, has been recommended by some, but not all, national organizations. Methods: We analyzed 2010 National Health Interview Survey data, including new CT colonography questions, from respondents ages 50 to 75 years (N = 8,952). We (i) assessed prevalence of CRC test use overall, by test type, and by sociodemographic and health care access factors and (ii) assessed reported reasons for not having a CRC test. Results: The age-standardized percentage of respondents reporting FOBT, sigmoidoscopy, or colonoscopy within recommended time intervals was 58.3% [95% confidence interval (CI), 57.0–59.6]. Colonoscopy was the most commonly reported test [within past 10 years: 54.6% (95% CI, 53.2–55.9)]. Home FOBT and sigmoidoscopy with FOBT were less frequently used [FOBT within past year: 8.8% (95% CI, 8.1–9.6); sigmoidoscopy within past 5 years with FOBT within past 3 years: 1.3% (95% CI, 1.0–1.6)]. CT colonography was rare: 1.3% (95% CI, 1.0–1.7). Increasing age, education, income, having health care insurance, and having a usual source of health care were associated with higher CRC test use. Test use within recommended time intervals was particularly low among individuals ages 50 to 64 years without health care insurance [21.2% (95% CI, 18.3–24.4)]. The most common reason for nonuse was “no reason or never thought about it.” Conclusions: About 40% of Americans ages 50 to 75 years do not meet the recommendations for having CRC screening tests. Impact: Expanded health care coverage and greater awareness of CRC screening are needed to further decrease CRC mortality. Cancer Epidemiol Biomarkers Prev; 21(6); 895–904. ©2012 AACR.


Morbidity and Mortality Weekly Report | 2017

Cancer Screening Test Use — United States, 2015

Arica White; Trevor D. Thompson; Mary C. White; Susan A. Sabatino; Janet S. de Moor; Paul V. Doria-Rose; Ann M. Geiger; Lisa C. Richardson

Healthy People 2020 (HP2020) includes objectives to increase screening for breast, cervical, and colorectal cancer (1) as recommended by the U.S. Preventive Services Task Force (USPSTF).* Progress toward meeting these objectives is monitored by measuring cancer screening test use against national targets using data from the National Health Interview Survey (NHIS) (1). Analysis of 2015 NHIS data indicated that screening test use remains substantially below HP2020 targets for selected cancer screening tests. Although colorectal cancer screening test use increased from 2000 to 2015, no improvements in test use were observed for breast and cervical cancer screening. Disparities exist in screening test use by race/ethnicity, socioeconomic status, and health care access indicators. Increased measures to implement evidence-based interventions and conduct targeted outreach are needed if the HP2020 targets for cancer screening are to be achieved and the disparities in screening test use are to be reduced.


Cancer | 2009

Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer

Dale Hardy; Chih Chin Liu; Rui Xia; Janice N. Cormier; Wenyaw Chan; Arica White; Keith D. Burau; Xianglin L. Du

This study investigated whether there was a significant gap in receipt of treatment for nonsmall cell lung cancer (NSCLC) between blacks and whites, and whether the gap or disparity changed during the past 12 years from 1991 to 2002.


Cancer | 2010

Racial disparities in colorectal cancer survival: to what extent are racial disparities explained by differences in treatment, tumor characteristics, or hospital characteristics?

Arica White; Sally W. Vernon; Luisa Franzini; Xianglin L. Du

Racial/ethnic differences in colorectal cancer (CRC) survival have been documented throughout the literature. However, the reasons for these disparities are difficult to decipher. The objective of this analysis was to determine the extent to which racial/ethnic disparities in survival are explained by differences in sociodemographics, tumor characteristics, diagnosis, treatment, and hospital characteristics.


Cancer | 2012

Racial and regional disparities in lung cancer incidence

J. Michael Underwood; Julie S. Townsend; Eric Tai; Shane P. Davis; Sherri L. Stewart; Arica White; Behnoosh Momin; Temeika L. Fairley

Lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer‐related death in the United States (US). We examined data from 2004 to 2006 for lung cancer incidence rates by demographics, including race and geographic region, to identify potential health disparities.


Cancer Epidemiology, Biomarkers & Prevention | 2011

Racial and Ethnic Disparities in Colorectal Cancer Screening Persisted Despite Expansion of Medicare's Screening Reimbursement

Arica White; Sally W. Vernon; Luisa Franzini; Xianglin L. Du

Objective: We examined the effect of Medicares expansion of colorectal cancer (CRC) screening test reimbursement on racial/ethnic disparities in CRC screening. Methods: CRC screening was ascertained for Medicare beneficiaries (n = 30,893), aged 70 to 89, who had no history of any tumor and resided in 16 Surveillance, Epidemiology and End Results regions of the United States from 1996 to 2005. CRC screening tests were identified in the 5% sample of Medicare claims. Age–gender-adjusted percentages and -adjusted odds of receiving any guideline-specific CRC screening [i.e., annual fecal occult blood test (FOBT), sigmoidoscopy every 5 years or colonoscopy every 10 years] by race/ethnicity and Medicare coverage expansion period (i.e., prior to FOBT coverage, FOBT coverage only, and post–colonoscopy coverage) were reported. Results: CRC screening increased as Medicare coverage expanded for white and black Medicare beneficiaries. However, blacks were less likely than whites to receive screening prior to FOBT coverage (OR = 0.74, 95% CI: 0.61–0.90), during FOBT coverage only (OR = 0.66, 95% CI: 0.52–0.83) and after colonoscopy coverage (OR = 0.80, 95% CI: 0.68–0.95). Hispanics were less likely to receive screening after colonoscopy coverage (OR = 0.73, 95% CI: 0.54–0.99). Conclusions: Despite the expansion of Medicare coverage for CRC screening tests, racial/ethnic differences in CRC screening persisted over time in this universally insured population, especially for blacks and Hispanics. Future studies should explore other factors beyond health insurance that may contribute to screening disparities in this and younger populations. Impact: Although CRC screening rates increased over time, they were still low according to recommendations. More effort is needed to increase CRC screening among all Medicare beneficiaries. Cancer Epidemiol Biomarkers Prev; 20(5); 811–7. ©2011 AACR.


Cancer | 2008

Racial disparities and treatment trends in a large cohort of elderly African Americans and Caucasians with colorectal cancer, 1991 to 2002

Arica White; Chih Chin Liu; Rui Xia; Keith D. Burau; Janice N. Cormier; Wenyaw Chan; Xianglin L. Du

Racial differences have been demonstrated in patients who receive treatment for colorectal cancer. However, little is known about whether these disparities have changed over time. The objective of this study was to determine whether racial disparities in receiving standard therapy have declined between 1991 and 2002.


American Journal of Public Health | 2014

Breast Cancer Mortality Among American Indian and Alaska Native Women, 1990–2009

Arica White; Lisa C. Richardson; Chunyu Li; Donatus U. Ekwueme; Judith S. Kaur

OBJECTIVES We compared breast cancer death rates and mortality trends among American Indian/Alaska Native (AI/AN) and White women using data for which racial misclassification was minimized. METHODS We used breast cancer deaths and cases linked to Indian Health Service (IHS) data to calculate age-adjusted rates and 95% confidence intervals (CIs) by IHS-designated regions from 1990 to 2009 for AI/AN and White women; Hispanics were excluded. Mortality-to-incidence ratios (MIR) were calculated for 1999 to 2009 as a proxy for prognosis after diagnosis. RESULTS Overall, the breast cancer death rate was lower in AI/AN women (21.6 per 100,000) than in White women (26.5). However, rates in AI/ANs were higher than rates in Whites for ages 40 to 49 years in the Alaska region, and ages 65 years and older in the Southern Plains region. White death rates significantly decreased (annual percent change [APC] = -2.1; 95% CI = -2.3, -2.0), but regional and overall AI/AN rates were unchanged (APC = 0.9; 95% CI = 0.1, 1.7). AI/AN women had higher MIRs than White women. CONCLUSIONS There has been no improvement in death rates among AI/AN women. Targeted screening and timely, high-quality treatment are needed to reduce mortality from breast cancer in AI/AN women.


Journal of Womens Health | 2014

Socioeconomic Disparities in Breast Cancer Treatment Among Older Women

Arica White; Lisa C. Richardson; Helen Krontiras; Maria Pisu

BACKGROUND Racial disparities in breast cancer treatment among Medicare beneficiaries have been documented. This study aimed to determine whether racial disparities exist among white and black female Medicare beneficiaries in Alabama, an economically disadvantaged U.S. state. METHODS From a linked dataset of breast cancer cases from the Alabama Statewide Cancer Registry and fee-for-service claims from Medicare, we identified 2,097 white and black females, aged 66 years and older, who were diagnosed with stages 1-3 breast cancer from January 1, 2000, to December 31, 2002. Generalized estimating equation (GEE) models were used to determine whether there were racial differences in initiating and completing National Comprehensive Cancer Network Clinical Practice guideline-specific treatment. RESULTS Sixty-two percent of whites and 64.7% of blacks had mastectomy (p=0.27); 34.6% of whites and 30.2% of blacks had breast conserving surgery (BCS) (p=0.12). Among those who had BCS, 76.8% of whites and 83.3% of blacks started adjuvant radiation therapy (p=0.33) and they equally completed adjuvant radiation therapy (p=0.29). For women with tumors over 1 centimeter, whites and blacks were equally likely to start (16.1% of whites and 18.3% of black; p=0.34) and complete (50.6% of whites and 46.3% of black; p=0.87) adjuvant chemotherapy. There were still no differences after adjusting for confounders using GEE. However, differences were observed by area-level socioeconomic status (SES), with lower SES residents more likely to receive a mastectomy (odds ratio [OR]=1.26; 95% confidence interval [CI]: 1.01-1.57) and initiate radiation after BCS (OR=2.24; 95% CI: 1.28-3.93). CONCLUSIONS No racial differences were found in guideline-specific breast cancer treatment or treatment completion, but there were differences by SES. Future studies should explore reasons for SES differences and whether similar results hold in other economically disadvantaged U.S. states.


American Journal of Preventive Medicine | 2014

Health and Economic Impact of Breast Cancer Mortality in Young Women, 1970–2008

Donatus U. Ekwueme; Gery P. Guy; Sun Hee Rim; Arica White; Ingrid J. Hall; Temeika L. Fairley; Hazel D. Dean

BACKGROUND Breast cancer is the second-leading cause of cancer-related deaths among women aged <50 years. Studies on the effects of breast cancer mortality among young women are limited. PURPOSE To assess trends in breast cancer mortality rates among women aged 20-49 years, estimate years of potential life lost (YPLL), and the value of productivity losses due to premature mortality. METHODS Age-adjusted rates and rate ratios (RRs) were calculated using 1970-2008 U.S. mortality data. Breast cancer mortality rates over time were assessed using Joinpoint regression modeling. YPLL was calculated using number of cancer deaths and the remaining life expectancy at the age of death. Value of productivity losses was estimated using the number of deaths and the present value of future lifetime earnings. RESULTS From 1970 to 2008, the age-adjusted breast cancer mortality rate among young women was 12.02/100,000. Rates were higher in the Northeast (RR=1.03, 95% CI, 1.02-1.04). The annual decline in breast cancer mortality rates among blacks was smaller (-0.68%) compared with whites (-2.02%). The total number of deaths associated with breast cancer was 225,866, which accounted for an estimated 7.98 million YPLL. The estimated total productivity loss in 2008 was

Collaboration


Dive into the Arica White's collaboration.

Top Co-Authors

Avatar

Donatus U. Ekwueme

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Sun Hee Rim

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Sally W. Vernon

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Temeika L. Fairley

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Xianglin L. Du

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Jessica B. King

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jun Li

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Lisa C. Richardson

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Djenaba A. Joseph

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jan M. Eberth

University of Texas MD Anderson Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge